Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q1 2020 · 10-Q
Revenue$0.00$0.00— vs Q1 2019 Net Income-$1.71M-$1.71MN/M vs Q1 2019 EPS Diluted-$0.02-$0.02N/M vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
$1,070,000
N/M
Operating Cash Flow-$223,000N/M ended Mar 31, 2020 · filed May 15, 2020 · 45 d after period end